CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective

CDK4/6 inhibitors have become game-changers in the treatment of estrogen receptor-positive (ER+) breast cancer, and in combination with endocrine therapy are the standard of care first-line treatment for ER+/HER2-negative advanced breast cancer. Although CDK4/6 inhibitors prolong survival for these...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fiona H., Downton, Teesha, Freelander, Allegra, Hurwitz, Joshua, Caldon, C. Elizabeth, Lim, Elgene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073728/
https://www.ncbi.nlm.nih.gov/pubmed/37035239
http://dx.doi.org/10.3389/fcell.2023.1148792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073728/
https://www.ncbi.nlm.nih.gov/pubmed/37035239
http://dx.doi.org/10.3389/fcell.2023.1148792

Ejemplares similares